Skip to main content
. 2024 May 4;271(7):4495–4502. doi: 10.1007/s00415-024-12360-x

Table 2.

Adverse events in the enrolled cohort

Adverse events, n (%) OCR (n = 216)
Upper respiratory tract infections 30 (13.9)
Headache 20 (9.3)
Urinary tract infections 9 (4.2)
Adverse events, n (%) OFA (n = 180)
Flu like syndrome* 31 (17.2)
Upper respiratory tract infections 20 (11.1)
Urinary tract infection 6 (3.3)
Urticaria* 4 (2.2)
Headache 3 (1.7)

OCR, ocrelizumab; OFA, ofatumumab

*At the first administration